Exclusive Summary

• Captopril is listed on the WHO Essential Medicines List and is a guideline-recommended first-line treatment for hypertension, heart failure, and diabetic nephropathy, ensuring strong and sustained global prescription demand.
• The product holds FDA GMP certification and is registered in the US, providing a powerful quality credential that is recognized or referenced by regulatory authorities in Southeast Asia, the Middle East, and parts of Africa, facilitating market entry.
• With over 1.3 billion hypertensives and 64 million heart failure patients globally, the addressable patient population is enormous, and demand in LMICs for affordable cardiovascular medicines continues to grow.
• All original patents have been expired for over 30 years, the generic market is fully open, and Chinese manufacturers' cost advantages enable competitive pricing suited for government tenders, NGO procurement, and price-sensitive markets.
• Four dosage strengths (12.5mg, 25mg, 50mg, 100mg) are available, covering the full titration range required by clinical practice and satisfying diverse market prescribing habits in a single supply source.